<DOC>
	<DOCNO>NCT00692380</DOCNO>
	<brief_summary>Radiation therapy technology allows increase radiation dose tumor spar healthy tissue improve balance complication cure .</brief_summary>
	<brief_title>Gated Intensity Modulated Radiation Therapy Concurrent Chemotherapy Inoperable NSCLC</brief_title>
	<detailed_description>The primary objective establish maximum tolerated fractional dose ( MTfD ) radiotherapy total dose 78Gy use gate IMRT , deliver single daily fraction administer concurrently Taxol® carboplatin chemotherapy . Secondary objective include : evaluate toxicity concurrent Taxol® carboplatin gate IMRT ; identify partial organ tolerance dos lung esophagus treat involved field thoracic 3D ; estimate complete response rate define PET perform 3 month completion therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients histologicallyproven , biopsy cytology , unresectable lung cancer follow histologic type : squamous cell carcinoma , adenocarcinoma , large cell carcinoma , nonsmall cell carcinoma , otherwise specify . Patient AJCC Stage IIIAIIIB , detectable tumor encompass radiation therapy field , include primary tumor involve regional lymph node . 18fluoro2deoxyglucose positron emission tomography require staging image fusion treatment planning . Atelectasis , present , must less one lung . Patients must granulocytes &gt; 1500/µl ; platelet &gt; 100,000/µl ; bilirubin &lt; 1.5 mg/dl ; AST ( SGOT ) &lt; 2 ULN ; serum creatinine &lt; 2.0 mg/dl . Zubrod Score 01 . FEV1 must &gt; 1.0 L. Patients must sign studyspecific inform consent form prior study entry Patients must measurable disease planning CT . Patient must complete IMRT plan attend physician must review approve dose volume histogram follow ( base treatment plan Phase 4 dose level ) : total lung V20 &lt; 30 % , mean esophageal dose &lt; 34 Gy , esophageal V55 &lt; 30 % , heart V40 &lt; 50 % . No prior concurrent malignancy except nonmelanomatous skin cancer unless diseasefree one year ; prior lung cancer within last two year . No prior RT thorax . No previous chemotherapy previous biologic response modifier current lung cancer within past five ( 5 ) year . No distant metastasis supraclavicular lymph node involvement significant atelectasis . No clinically significant pleural effusion , pericardial effusion superior vena cava syndrome . Undifferentiated small cell ( oat cell high grade neuroendocrine ) carcinoma , stage . Stage I , II IV NSCLC . Complete tumor resection , recurrent disease , patient eligible definitive surgery . Concurrent malignancy except nonmelanomatous skin cancer prior cancer unless diseasefree one year . Prior radiation therapy thorax . Previous chemotherapy previous biologic response modifier current lung cancer within past five ( 5 ) year . Distant metastasis supraclavicular lymph node involvement , atelectasis entire lung . Patients pretreatment evaluation Section 4.0 evaluation perform &gt; 8 week prior study entry . Patients clinically significant pleural effusion , pericardial effusion superior vena cava syndrome . Prior lung cancer within last two year . Patients significant atelectasis CT definition gross tumor volume ( GTV ) difficult determine . Pregnant lactating female . It known effect treatment may develop fetus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>gate IMRT</keyword>
</DOC>